30 April 2020

Safety Updates for Pharmaceutical Products

Reference: CIR-2019-00000305

To all health facilities / all health care practitioners in Dubai's private health sector:

Referring to the above subject, DHA notes all health facilities regarding the Circular issued by the MOHAP for information and adhere to what is stated

• Add a warning to pharmaceuticals containing the active substance Febuxostat
• Recall one batch for pharmaceutical product Riazole 125mg per 5ml Oral Suspension
• Safety update of a pharmaceutical product Androcur ( cyproterone acetate )

  

Drug Control Section

Health Regulation Sector

DHA

Supporting Documents:

Add a warning to pharmaceuticals containing the active substance Febuxostat.pdf:

View Document

Recall one batch for pharmaceutical product Riazole 125mg 5ml Oral Suspension.pdf:

View Document

Safety update of a pharmaceutical product Androcur ( cyproterone acetate ).pdf:

View Document